Globus Medical Q1 Earnings Call Highlights

Globus Medical (NYSE:GMED) reported a beardown commencement to 2026, with first-quarter gross and net rising sharply arsenic the institution cited continued momentum successful U.S. spine, borderline enlargement and contributions from its Nevro acquisition.

President and Chief Executive Officer Keith Pfeil said the institution is “moving with intent and successful the close direction,” pointing to marketplace stock gains, caller merchandise launches and operational discipline. He besides highlighted the company’s broader advancement since fiscal 2022, saying gross has much than tripled, escaped currency travel has accrued sixfold, astir $1 cardinal successful indebtedness has been extinguished and much than $600 cardinal has been utilized to repurchase implicit 10 cardinal shares.

→ Uber's Annual Product Showcase Reveals It Is Coming for Airbnb and Booking

For the archetypal quarter, Globus reported gross of $759.9 million, up 27% arsenic reported and 25.5% connected a changeless currency basis. GAAP nett income was $124.3 million, oregon $0.90 per diluted share. Non-GAAP nett income was $154.9 million, producing afloat diluted non-GAAP net per stock of $1.12, up 64.7% from the prior-year quarter.

U.S. Spine Leads Base Business Growth

Globus’ basal concern gross totaled $677.2 million, up 13.2% arsenic reported. Pfeil said U.S. spine gross grew 10% successful the quarter, marking the 3rd consecutive 4th of 10% growth, portion Chief Financial Officer Kyle Kline cited 9.6% as-reported maturation for the category.

→ Wells Fargo’s Comeback Is Real—But Not Risk-Free

Pfeil said the U.S. spine concern has present recorded 58 consecutive weeks of growth. He attributed the show to cross-selling, competitory income typical recruiting and robotics pull-through, adding that maturation was wide crossed categories including modular fixation, minimally invasive pedicle screws, expandable TLIF, ALIF, posterior cervical and cervical plating.